|
Matrix metalloproteinases and Diabetic Nephropathy Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Matrix metalloproteinases and Diabetic Nephropathy conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Matrix metalloproteinases and Diabetic Nephropathy Clinical research trials and Matrix metalloproteinases and Diabetic Nephropathy medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Matrix metalloproteinases and Diabetic Nephropathy. Matrix metalloproteinases and Diabetic Nephropathy Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Matrix metalloproteinases and Diabetic Nephropathy clinical trial. Participants oftentimes recieve the finest healthcare available for their Matrix metalloproteinases and Diabetic Nephropathy condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Matrix metalloproteinases and Diabetic Nephropathy  Matrix metalloproteinases and Diabetic Nephropathy
Matrix metalloproteinases and Diabetic Nephropathy
For Condition: Diabetic Nephropathy,Diabetes Mellitus, Type 1
Status: Recruiting
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ,
Synopsis: Matrix metalloproteinases (MMPs) are a family of protein-degrading enzymes that are involved in the breakdown and remodeling of many tissues and organs. Abnormal activity of these enzymes has been implicated in many disease processes including rheumatoid arthritis, dental disease and metastatic cancer. Recent studies also suggest that elevations in blood sugar may abnormally effect MMP enzyme activity. Decreased activity of some of these MMP enzymes may be a partial cause of the abnormal enlargement of the kidney (renal hypertrophy) seen at the start of diabetic kidney disease (nephropathy). Preliminary clinical data from our laboratory confirm that children with newly diagnosed type 1 diabetes mellitus (DM) have lower blood levels of some of these enzymes at the time of very high blood sugar readings. However, these enzyme levels become normal again as blood sugar levels improve with insulin treatment. In the present study, we propose to investigate the hypothesis that MMPs are involved in the cause of diabetic kidney disease by measuring concentrations of specific MMPs and some related proteins in the blood and urine of patients with type 1 DM who are between the ages of 14-40 years. We will enroll some patients who are recently diagnosed with diabetes, some who have had diabetes for several years, but without signs of kidney disease, and some with long-term diabetes and various degrees of kidney disease. Continuous Subcutaneous Glucose Monitoring, conducted for 3-4 days, will also be provided as a part of this study, to determine how different levels of blood sugar control might relate to different levels of MMP enzyme activity in the blood. We anticipate that this study will help to establish a link between abnormal MMP activity and the cause of nephropathy in type 1 DM, allowing scientists to design better therapies for the prevention and treatment of diabetes-related kidney problems.
Details:
Eligibility:
Study Type: Observational, Screening, Cross-Sectional, Defined Population, Prospective Study
Minimum Age/Maximum Age: 14 Years/40 Years
Genders: Both
Protocol Entry Criteria: Type 1 Diabetes with or without kidney disease and past puberty.
Total Enrollment: 330
Location and Contact Information:
Arkansas Children's Hospital/University of Arkansas for Medical Sciences *Recruiting*
Little Rock, Arkansas, 72202
United States
Recruiting Cynthia Moreau 501-364-1975
Additional Information:
Study ID Numbers: MMADN;
Study Start Date: March 2003
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00067886
Other Diabetes Mellitus, Type 1 Studies:
1. Soy Protein in Early Diabetic Nephropathy
2. Matrix metalloproteinases and Diabetic Nephropathy
3. Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes
4. Study of Drugs for High Blood Pressure and High Cholesterol in American Indians with Type 2 Diabetes at High Risk of Kidney or Heart Disease
5. The effect of LY333531 on protein in the urine in patients with type 2 diabetes.
Related Studies:
Other Diabetes Mellitus, Type 1 Clinical Trials
Other Arkansas Clinical Trials
Other Little Rock Clinical Trials
Matrix metalloproteinases and Diabetic Nephropathy
|
|
|
|
|
|
|
|
